ARCTURUS THERAPEUTICS HLDGS's ticker is ARCT and the CUSIP is 03969T109. A total of 156 filers reported holding ARCTURUS THERAPEUTICS HLDGS in Q3 2021. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $930,954 | -9.2% | 36,437 | +1.9% | 0.00% | 0.0% |
| Q2 2023 | $1,025,654 | +140593.3% | 35,762 | +17.6% | 0.00% | 0.0% |
| Q1 2023 | $729 | +47.3% | 30,399 | +4.2% | 0.00% | 0.0% |
| Q4 2022 | $495 | -99.9% | 29,180 | +3.2% | 0.00% | 0.0% |
| Q3 2022 | $419,000 | +3.7% | 28,265 | +10.0% | 0.00% | 0.0% |
| Q2 2022 | $404,000 | -44.4% | 25,698 | -4.6% | 0.00% | 0.0% |
| Q1 2022 | $726,000 | -33.1% | 26,927 | -8.2% | 0.00% | 0.0% |
| Q4 2021 | $1,086,000 | -23.3% | 29,339 | -1.0% | 0.00% | -50.0% |
| Q3 2021 | $1,416,000 | +46.0% | 29,642 | +3.4% | 0.00% | +100.0% |
| Q2 2021 | $970,000 | +9.9% | 28,667 | +34.1% | 0.00% | 0.0% |
| Q1 2021 | $883,000 | -18.0% | 21,380 | -13.9% | 0.00% | 0.0% |
| Q4 2020 | $1,077,000 | +49.0% | 24,833 | +47.3% | 0.00% | 0.0% |
| Q3 2020 | $723,000 | -10.7% | 16,864 | -2.6% | 0.00% | 0.0% |
| Q2 2020 | $810,000 | – | 17,323 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DFPG INVESTMENTS, LLC | 456,390 | $5,541,000 | 3.62% |
| DAFNA Capital Management LLC | 173,914 | $1,890,000 | 0.65% |
| One68 Global Capital, LLC | 19,861 | $216,000 | 0.47% |
| Diametric Capital, LP | 51,982 | $565,000 | 0.41% |
| ARK Investment Management | 1,383,756 | $15,041,000 | 0.38% |
| EAM Investors, LLC | 52,833 | $574,000 | 0.13% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 31,404 | $341,000 | 0.05% |
| Nikko Asset Management Americas, Inc. | 280,548 | $3,050,000 | 0.05% |
| MGO ONE SEVEN LLC | 14,900 | $161,000 | 0.04% |
| Qube Research & Technologies Ltd | 67,702 | $736,000 | 0.02% |